Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$20.26 0.18 (0.90%)
2/9/2010 4:00 PM

Affymax, Inc. (AFFY)

CAPS Rating:
*

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AFFY

Add Stock to Watchlist

What the Community Thinks

Total Members

39 Outperforms
38 Underperforms
 

All-Stars

18 Outperforms
18 Underperforms
 

Wall Street

5 Outperforms
0 Underperforms
 

Members bullish on AFFY are also bullish on:

Members bearish on AFFY are also bearish on:

Ticker Tags

Defensive (1457), Biotechnology (220), Healthcare (711), Micro Cap (4701), IPO in 2006 (145)
Suggest a tag

Affymax, Inc. At A Glance

Current Price: $20.26
Last Trade Time: 2/9/2010 4:00 PM
Open: $20.41
Previous Close: $20.08
Daily Range: $19.86 - $20.67
52-Week Range: $11.79 - $25.64
Volume: 54,904
Market Cap: $387.42M
P/E Ratio: 1.83
Compare Our Special Broker Offers!

Stock Trends

AFFY VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Affymax, Inc. (AFFY)

Avatar zzlangerhans (99.64) Submitted: 11/24/08 12:22 PM

I continue my attempts to gauge Affymax swings. Now that they are back in the low end of range, I'm going to guess that they survive the current market unpleasantness without plumbing new lows thanks to a relatively strong cash position and the ongoing phase III trials.

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1

Affymax, Inc. (AFFY)

Avatar zzlangerhans (99.64) Submitted: 12/18/09 12:45 AM

I don't have anything against Hematide, but I think the current market cap of Affymax is excessive considering that it depends entirely on the success of that compound. While many stocks such as Poniard and Mannkind have shown a tendency to rise approaching a major binary catalyst, I suspect Affymax...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 9 :   1 2 Next »

Recs

1

 (AFFY)

Avatar zzlangerhans (99.64) Submitted: 12/18/09 12:45 AM : Underperform Start Price: $23.15 AFFY Score: 9.80

I don't have anything against Hematide, but I think the current market cap of Affymax is excessive considering that it depends entirely on the success of that compound. While many stocks such as Poniard and Mannkind have shown a tendency to rise approaching a major binary catalyst, I suspect Affymax will fall as Q2 2010 approaches when investors realize they are looking at an 80% or greater haircut if the phase III trials fail. Perhaps I'm wrong, but how many times have I been right about this stock before? Go ahead, check it out.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AFFY)

Avatar crichton1 (23.23) Submitted: 10/09/09 5:54 PM : Outperform Start Price: $22.79 AFFY Score: -10.60

competitive product to Amgen's EPO on the horizon.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AFFY)

Avatar power2macs (< 20) Submitted: 7/08/09 3:13 AM : Outperform Start Price: $17.84 AFFY Score: -8.04

the co hasnt had any major catalysts for a while since its in the middle of a moderately large phase iii program. as the market begins to remember that affys pivotal data is coming up it will also recall that the market for their drug hematide is absolutely massive.

there are some caveats to the large mkt opp (jnj litigation, potential generic biologics legislation, and a stagnant market for ESAs), but despite this the co remains dramatically undervalued, particularly considering their $150m cash balance (which mgmt has said will not be sufficient to carry them thru to profitability tho).

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AFFY)

Avatar cashsage (32.22) Submitted: 6/02/09 6:41 AM : Underperform Start Price: $17.27 AFFY Score: -2.55

AFFY has a too high valuation compared to its sales potential. It is also one of the most loss making companies at least until 2010.
Moreover the company has less than 150 shareholders, 128, on 2009-03-12, and the company is diluting the existing shareholders, adding 24% more outstanding shares from 2008-03 to 2009-03.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AFFY)

Avatar chk999 (99.99) Submitted: 5/22/09 11:46 AM : Underperform Start Price: $15.33 AFFY Score: -11.39

Speculative biotech during a bad economy sounds pretty iffy.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 9 :   1 2 Next »

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackStanfordRes 85.54 09/24/08 Outperform NS $18.90+7.20%-7.53%+14.72
TrackRWBaird 87.00 07/02/08 Outperform NS $16.15+25.45%-14.19%+39.64
TrackRBCCapMkts 86.33 07/17/07 Outperform NS $27.56-26.49%-27.32%+0.83
TrackCowenandCo 86.76 03/14/07 Outperform NS $31.50-35.68%-17.79%-17.89

Results 1 - 5 of 5  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 375ms